Having trouble accessing articles? Reset your cache.

NeRRe hopes to advance cough candidate despite Phase II miss

While NeRRe's orvepitant missed the primary endpoint of the Phase IIb VOLCANO-2 trial, the company believes the trial's patient-reported outcomes support advancement of the refractory chronic cough therapy

Read the full 285 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE